<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5: Summary of Effect of Coadministered Drugs on Exposure to Asenapine in Healthy Volunteers</caption>
<col align="center" valign="middle" width="25%"></col>
<col align="center" valign="middle" width="23%"></col>
<col align="center" valign="middle" width="14%"></col>
<col align="center" valign="middle" width="9%"></col>
<col align="center" valign="middle" width="9%"></col>
<col align="center" valign="middle" width="20%"></col>
<thead>
<tr>
<th rowspan="2" stylecode="Lrule Rrule">Coadministered drug <br/>(Postulated effect on CYP450/UGT)</th>
<th colspan="2" stylecode="Rrule Botrule">Dose schedules</th>
<th colspan="2" stylecode="Rrule Botrule">Effect on asenapine pharmacokinetics</th>
<th stylecode="Rrule">Recommendation</th>
</tr>
<tr>
<th stylecode="Rrule">Coadministered drug</th>
<th stylecode="Rrule">Asenapine</th>
<th stylecode="Rrule">C<sub>max</sub>
</th>
<th stylecode="Rrule">AUC<sub>0-∞</sub>
</th>
<th stylecode="Rrule"></th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fluvoxamine<br/>(CYP1A2 inhibitor)<br/>
</td>
<td stylecode="Rrule">25 mg twice daily for 8 days</td>
<td stylecode="Rrule">5-mg Single Dose</td>
<td stylecode="Rrule">+13%</td>
<td stylecode="Rrule">+29%</td>
<td stylecode="Rrule">Coadminister with caution<footnote>The full therapeutic dose of fluvoxamine would be expected to cause a greater increase in asenapine plasma concentrations. AUC: Area under the curve.</footnote>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Paroxetine<br/>(CYP2D6 inhibitor)</td>
<td stylecode="Rrule">20 mg once daily for 9 days</td>
<td stylecode="Rrule">5-mg Single Dose</td>
<td stylecode="Rrule">–13%</td>
<td stylecode="Rrule">–9%</td>
<td stylecode="Rrule">No SAPHRIS dose adjustment required <content stylecode="italics">[see <linkhtml href="#S7.2">Drug Interactions (7.2)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Imipramine<br/>(CYP1A2/2C19/3A4 inhibitor)</td>
<td stylecode="Rrule">75-mg Single Dose</td>
<td stylecode="Rrule">5-mg Single Dose</td>
<td stylecode="Rrule">+17%</td>
<td stylecode="Rrule">+10%</td>
<td stylecode="Rrule">No SAPHRIS dose adjustment required</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Cimetidine<br/>(CYP3A4/2D6/1A2 inhibitor)</td>
<td stylecode="Rrule">800 mg twice daily for 8 days</td>
<td stylecode="Rrule">5-mg Single Dose</td>
<td stylecode="Rrule">–13%</td>
<td stylecode="Rrule">+1%</td>
<td stylecode="Rrule">No SAPHRIS dose adjustment required</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Carbamazepine<br/>(CYP3A4 inducer)</td>
<td stylecode="Rrule">400 mg twice daily for 15 days<br/>
</td>
<td stylecode="Rrule">5-mg Single Dose</td>
<td stylecode="Rrule">–16%</td>
<td stylecode="Rrule">–16%</td>
<td stylecode="Rrule">No SAPHRIS dose adjustment required</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Valproate<br/>(UGT1A4 inhibitor)</td>
<td stylecode="Rrule">500 mg twice daily for 9 days</td>
<td stylecode="Rrule">5-mg Single Dose</td>
<td stylecode="Rrule">2%</td>
<td stylecode="Rrule">–1%</td>
<td stylecode="Rrule">No SAPHRIS dose adjustment required</td>
</tr>
</tbody>
</table>